Skip to main content

Advertisement

SpringerLink
Log in

Pharmacological treatments for cutaneous manifestations of inherited ichthyoses

  • Review
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

Inherited ichthyoses are a group of etiologically heterogeneous diseases that affect the function of the skin and that are classified as syndromic and non-syndromic entities. Irrespective of the type, all these disorders are generally produced by mutations in genes involved in a variety of cellular functions in the skin. These mutations lead to disruption of the stratum corneum and impairment of the skin barrier, producing clinical features such as hyperkeratosis, skin scaling, erythema, fissures, pruritus, inflammation, and skin pain. Despite advances in the knowledge of the pathogenesis of ichthyoses, there is, to our knowledge, no definitive cure for skin manifestations, and current treatments consist of moisturizers, emollients, and keratolytic agents. In this respect, the development of new formulations based on nanotechnology could be useful to enhance their therapeutic effectiveness. In this article, we provide a comprehensive description of pharmacological treatments for cutaneous manifestations in patients with inherited ichthyosis and discuss novel approaches with therapeutic potential for this purpose. Moreover, we offer an overview of toxicity concerns related to these treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Akiyama M (2011) Updated molecular genetics and pathogenesis of ichthiyoses. Nagoya J Med Sci 73(3–4):79–90

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Yoneda K (2016) Inherited ichthyosis: syndromic forms. J Dermatol 43(3):252–263

    Article  PubMed  Google Scholar 

  3. Oji V, Tadini G, Akiyama M, Blanchet Bardon C, Bodemer C, Bourrat E et al (2010) Revised nomenclature and classification of inherited ichthyoses: results of the first ichthyosis consensus conference in Soreze 2009. J Am Acad Dermatol 63(4):607–641

    Article  PubMed  Google Scholar 

  4. Oji V, Preil M, Kleinow B, Wehr G, Fischer J, Hennies HC et al (2017) S1 guidelines for the diagnosis and treatment of ichthyoses—update. J Ger Soc Dermatol 15(10):1053–1065

    Google Scholar 

  5. Hernández-Martin A, Aranegui B, Martin-Santiago A, Garcia-Doval I (2013) A systematic review of clinical trials of treatments for the congenital ichthyoses, excluding ichthyosis vulgaris. J Am Acad Dermatol 69(4):544–549

    Article  CAS  PubMed  Google Scholar 

  6. Kolarsick PAJ, Kolarsickk MA, Goodwin C (2011) Anatomy and physiology of the skin. J Dermatol Nurses Assoc 3(4):203–213

    Article  Google Scholar 

  7. Chavanas S, Bodemer C, Rochat A, Hamel-Teillac D, Ali M, Irvine AD et al (2000) Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet 25(2):141–142

    Article  CAS  PubMed  Google Scholar 

  8. De Laurenzi V, Rogers GR, Hamrock DJ, Marekov LN, Steinert PM, Comptom JG et al (1996) Sjögren–Larsson syndrome is caused by mutations in the fatty aldehyde dehydrogenase gene. Nat Genet 12:52–57

    Article  PubMed  Google Scholar 

  9. Hernández-Martín A, González-Sarmiento R (2015) Recent advances in congenital ichthyoses. Curr Opin Pediatr 27(4):473–479

    Article  PubMed  Google Scholar 

  10. Raghunath M, Hennies HC, Ahvazi B, Vogel M, Reis A, Steinert PM et al (2003) Self-healing collodion baby: a dynamic phenotype explained by a particular transglutaminase-1 mutation. J Investig Dermatol 120(2):224–228

    Article  CAS  PubMed  Google Scholar 

  11. Eckl KM, Tidhar R, Thiele H, Oji V, Hausser I, Brodesser S et al (2013) Impaired epidermal ceramide synthesis causes autosomal recessive congenital ichthyosis and reveals the importance of ceramide acyl chain length. J Investig Dermatol 133(9):2202–2211

    Article  CAS  PubMed  Google Scholar 

  12. Akiyama M (2014) The roles of ABCA12 in epidermal lipid barrier formation and keratinocyte differentiation. Biochim Biophys Acta Mol Cell Biol Lipids 1841(3):435–440

    Article  CAS  Google Scholar 

  13. Deffenbacher B (2013) Successful experimental treatment of congenital ichthyosis in an infant. BMJ Case Rep. https://doi.org/10.1136/bcr-2013-008688

    Article  PubMed  PubMed Central  Google Scholar 

  14. Fluhr JW, Gloor M, Lehmann L, Lazzerini S, Distante F, Berardesca E (1999) Glycerol accelerates recovery of barrier function in vivo. Acta Derm Venereol 79(6):418–421

    Article  CAS  PubMed  Google Scholar 

  15. Ganemo A, Virtanen M, Vahlquist A (1999) Improved topical treatment of lamellar ichthyosis: a double-blind study of four different cream formulations. Br J Dermatol 141:1027–1032

    Article  CAS  PubMed  Google Scholar 

  16. Fleckman P, Newell BD, Van Steensel MA, Yan AC (2013) Topical treatment of ichthyoses. Dermatol Ther 26(1):16–25

    Article  PubMed  Google Scholar 

  17. Vahlquist A, Gånemo A, Virtanen M (2008) Congenital ichthyosis: an overview of current and emerging therapies. Acta Derm Venereol 88(1):4–14

    Article  PubMed  Google Scholar 

  18. Björklund S, Engblom J, Thuresson K, Sparr E (2013) Glycerol and urea can be used to increase skin permeability in reduced hydration conditions q. Eur J Pharm Sci 50(5):638–645

    Article  CAS  PubMed  Google Scholar 

  19. Blanchet-Bardon C, Tadini G, MacHado Matos M, Delarue A (2012) Association of glycerol and paraffin in the treatment of ichthyosis in children: an international, multicentric, randomized, controlled, double-blind study. J Eur Acad Dermatol Venereol 26(8):1014–1019

    Article  CAS  PubMed  Google Scholar 

  20. Lorencini M, Brohem CA, Dieamant GC, Zanchin NIT, Maibach HI (2014) Active ingredients against human epidermal aging. Ageing Res Rev 15(1):100–115

    Article  CAS  PubMed  Google Scholar 

  21. Tadini G, Giustini S, Milani M (2011) Efficacy of topical 10% urea-based lotion in patients with ichthyosis vulgaris: a two-center, randomized, controlled, single-blind, right- vs. -left study in comparison with standard glycerol-based emollient cream. Curr Med Res Opin 27(12):2279–2284

    Article  CAS  PubMed  Google Scholar 

  22. Danby SG, Higgs-bayliss T, Chittock J, Albenali L, Cork J (2016) The effect of an emollient containing urea, ceramide NP, and lactate on skin barrier structure and function in older people with dry skin. Skin Pharmacol Physiol 29:135–147

    Article  CAS  PubMed  Google Scholar 

  23. Küster W, Bohnsack K, Rippke F, Upmeyer H-J, Groll S, Traupe H (1998) Efficacy of urea therapy in children with ichthyosis. Dermatology 196:217–222

    Article  PubMed  Google Scholar 

  24. Celleno L (2018) Topical urea in skincare: a review. Dermatol Ther 31(6):e12690

    Article  PubMed  Google Scholar 

  25. Data A, Bv I (2004) Emollients and keratolytics remain the mainstay of therapy for patients with ichthyosis. Drugs Ther Perspect 20(2):11–15

    Article  Google Scholar 

  26. Khalil S, Bardawil T, Saade S, Chedraoui A, Ramadan N, Hasbani DJ et al (2018) Use of topical glycolic acid plus a lovastatin-cholesterol combination cream for the treatment of autosomal recessive congenital ichthyoses. JAMA Dermatol 154(11):1320–1323

    Article  PubMed  PubMed Central  Google Scholar 

  27. Bashir SJ, Dreher F, Chew AL, Zhai H, Levin C, Stern R et al (2005) Cutaneous bioassay of salicylic acid as a keratolytic. Int J Pharm 292:187–194

    Article  CAS  PubMed  Google Scholar 

  28. Lebwohl M (1999) The role of salicylic acid in the treatment of psoriasis. Int J Dermatol 38(1):16–24

    Article  CAS  PubMed  Google Scholar 

  29. Proksch E, De Bony R, Trapp S, Boudon S (2017) Topical use of dexpanthenol: a 70th anniversary article. J Dermatol Treat 28(8):766–773

    Article  CAS  Google Scholar 

  30. Proksch E, Nissen H (2002) Dexpanthenol enhances skin barrier repair and reduces inflammation after sodium lauryl sulphate-induced irritation. J Dermatolog Treat 13(4):173–178

    Article  CAS  PubMed  Google Scholar 

  31. Biro K, Thacy D, Ochsendorf FR, Kaufmann R, Boehncke W-H (2003) Efficacy of dexpanthenol in skin protection against irritation: a double-blind, placebo-controlled study. Contact Dermat 49:80–84

    Article  CAS  Google Scholar 

  32. Heise R, Skazik C, Marquardt Y, Czaja K, Sebastian K, Kurschat P et al (2012) Dexpanthenol modulates gene expression in skin wound healing in vivo. Skin Pharmacol Physiol 25(5):241–248

    Article  CAS  PubMed  Google Scholar 

  33. Thomas JR, Dixon TK, Bhattacharyya TK (2013) Effects of topicals on the aging skin process. Facial Plast Surg Clin N Am 21(1):55–60

    Article  Google Scholar 

  34. Milanese A, Gorincioi E, Rajabi M, Vistoli G, Santaniello E (2011) New synthesis of 6[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid and evaluation of the influence of adamantyl group on the DNA binding of a naphthoic retinoid. Bioorg Chem 39(4):151–158

    Article  CAS  PubMed  Google Scholar 

  35. Piskin S, Uzunali E (2007) A review of the use of adapalene for the treatment of acne vulgaris. Ther Clin Risk Manag 3(4):621–624

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Ogawa M, Akiyama M (2014) Successful topical adapalene treatment for the facial lesions of an adolescent case of epidermolytic ichthyosis. J Am Acad Dermatol 71(3):e103–e105

    Article  PubMed  Google Scholar 

  37. Verschoore M, Poncet M, Czernielewski J, Sorba V, Clucas A (1997) Adapalene 0.1% gel has low skin-irritation potential. J Am Acad Dermatol 36(6):S104–S109

    Article  CAS  PubMed  Google Scholar 

  38. Hofmann B, Stege H, Ruzicka T, Lehmann P (1999) Effect of topical tazarotene in the treatment of congenital ichthyoses. Br J Dermatol 141(4):642–646

    Article  CAS  PubMed  Google Scholar 

  39. Chandraratna RAS (1997) Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis. J Am Acad Dermatol 37(2 III SUPPL.):12–17

    Article  Google Scholar 

  40. Craiglow BG, Choate KA, Milstone LM (2013) Topical tazarotene for the treatment of ectropion in ichthyosis. JAMA Dermatol 149(5):598–600

    Article  PubMed  Google Scholar 

  41. Behera B, Chandrashekar L, Singh N, Thappa DM, Gochhait D (2017) Lamellar ichthyosis associated bilateral pseudoainhum of fingers and toes successfully treated with tazarotene. Dermatol Ther 30(5):3–5

    Article  Google Scholar 

  42. Takeuchi Y, Yasukawa H, Yamaoka Y, Kato Y, Morimoto Y, Fukumori Y, Fukuda T (1992) Effects of fatty acids, fatty amines and propylene glycol on rat stratum corneum lipids and proteins in vitro measured by Fourier transform infrared/attenuated total reflection (FT-IR/ATR) spectroscopy. Chem Pharm Bull 40(7):1887–1892

    Article  CAS  Google Scholar 

  43. Bowen JL, Heard CM (2006) Film drying and complexation effects in the simultaneous skin permeation of ketoprofen and propylene glycol from simple gel formulations. Int J Pharm 307(2):251–257

    Article  CAS  PubMed  Google Scholar 

  44. Catanzaro JM, Smith JG Jr, Augusta G (1991) Propylene glycol dermatitis. J Am Acad Dermatol 24(2):90–95

    Article  CAS  PubMed  Google Scholar 

  45. Lim TY, Poole RL, Pageler NM (2014) Propylene glycol toxicity in children. J Pediatr Pharmacol Ther 19:277–282

    PubMed  PubMed Central  Google Scholar 

  46. Fiume MM, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler D et al (2012) Safety assessment of propylene glycol, tripropylene glycol, and PPGs as used in cosmetics. Int J Toxicol 31:245S–260S

    Article  CAS  PubMed  Google Scholar 

  47. Andersen KE, Storrs FJ (1982) Skin irritation caused by propylene glycols. Hautarzt 33(1):12–14

    CAS  PubMed  Google Scholar 

  48. Roussel L, Atrux-Tallau N, Pirot F (2012) Glycerol as a skin barrier influencing humectant. In: Lodén M, Maibach HI (eds) Treatment of dry skin syndrome: the art and science of moisturizers. Springer, Berlin, pp 473–480

    Chapter  Google Scholar 

  49. Lodén M, Wessman C (2001) The influence of a cream containing 20% glycerin and its vehicle on skin barrier properties. Int J Cosmet Sci 23(2):115–119

    Article  PubMed  Google Scholar 

  50. DiGiovana J, Mauro T, Milstone L, Schmuth M, Toro J (2013) Systemic retinoids in the management of ichthyoses and related skin types. Dermatol Ther 26(1):26–38

    Article  Google Scholar 

  51. Virtanen M, Gedde-Dahl TJ, Mörk NJ, Leigh I, Bowden PE, Vahlquist A (2001) Phenotypic/genotypic correlations in patients with epidermolytic hyperkeratosis and the effects of retinoid therapy on keratin expression. Acta Derm Venereol 81(3):163–170

    Article  CAS  PubMed  Google Scholar 

  52. Vahlquist A, Blockhuys S, Steijlen P, Van Rossem K, Didona B, Blanco D et al (2014) Oral liarozole in the treatment of patients with moderate/severe lamellar ichthyosis: results of a randomized, double-blind, multinational, placebo-controlled phase II/III trial. Br J Dermatol 170(1):173–181

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Verfaille CJ, Vanhoutte FP, Blanchet-Bardon C, Van Steensel MA, Steijlen PM (2007) Oral liarozole vs. acitretin in the treatment of ichthyosis: a phase II/III multicentre, double-blind, randomized, active-controlled study. Br J Dermatol 156(5):965–973

    Article  CAS  PubMed  Google Scholar 

  54. Bodemer C, Bourrat E, Mazereeuw-Hautier J, Boralevi F, Barbarot S, Bessis D et al (2011) Short- and medium-term efficacy of specific hydrotherapy in inherited ichthyosis. Br J Dermatol 165(5):1087–1094

    Article  CAS  PubMed  Google Scholar 

  55. Madan RK, Levitt J (2014) A review of toxicity from topical salicylic acid preparations. J Am Acad Dermatol 70(4):788–792

    Article  CAS  PubMed  Google Scholar 

  56. Craiglow BG (2013) Ichthyosis in the newborn. Semin Perinatol 37(1):26–31

    Article  PubMed  PubMed Central  Google Scholar 

  57. Ramírez ME, Youseef WF, Romero RG, Martínez JMQ, González-Enseñat MA, Vilaplana XS et al (2006) Acute percutaneous lactic acid poisoning in a child. Pediatr Dermatol 23(3):282–285

    Article  PubMed  Google Scholar 

  58. Davies MG, Vella Briffa D, Greaves MW (1979) Systemic toxicity from topically applied salicylic acid. Br Med J 1:661

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Fernandes NF, Janniger CK, Schwartz RA (2010) X-linked ichthyosis: an oculocutaneous genodermatosis. J Am Acad Dermatol 62(3):480–485

    Article  PubMed  Google Scholar 

  60. Chamcheu JC, Wood GS, Siddiqui IA, Syed DN, Adhami VM, Teng JM et al (2012) Progress towards genetic and pharmacological therapies for keratin genodermatoses: current perspective and future promise. Exp Dermatol 21(7):481–489

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Bassotti A, Moreno S, Criado E (2011) Successful treatment with topical N-acetylcysteine in urea in five children with congenital lamellar ichthyosis. Pediatr Dermatol 28(4):451–455

    Article  PubMed  Google Scholar 

  62. Batalla A, Dávila-Pousa C, Feal C, Flórez Á (2018) Topical carbocysteine: a new option for the treatment of ichthyosis. Pediatr Dermatol 35(6):e357–e359

    Article  PubMed  Google Scholar 

  63. Chouhan K, Sethuraman G, Gupta N, Sharma VK, Kabra M, Khaitan BK et al (2012) Vitamin D deficiency and rickets in children and adolescents with ichthyosiform erythroderma in type IV and V skin. Br J Dermatol 166(3):608–615

    Article  CAS  PubMed  Google Scholar 

  64. Sethuraman G, Marwaha RK, Challa A, Yenamandra VK, Ramakrishnan L, Thulkar S et al (2016) Vitamin D: a new promising therapy for congenital ichthyosis. Pediatrics 137(1):e20151313

    Article  Google Scholar 

  65. Del Rosso QJ (2013) Application of protease technology in dermatology: rationale for incorporation into skin care with initial observations on formulations designed for skin cleansing, maintenance of hydration, and restoration of the epidermal permeability barrier. J Clin Aesthet Dermatol 6(6):14–22

    PubMed  PubMed Central  Google Scholar 

  66. Buge JC et al (2018) No-rinse chemical foam containing trifarotene, and use thereof in the treatment of ichthyosis. Patent application publication. Pub. no. US2018/0333656 A1. US Pat. 1

  67. Ramot Y, Oláh A, Paus R (2018) Cover image: neuroendocrine treatment of inherited keratin disorders by cannabinoids? Br J Dermatol 178(6):1469

    Article  CAS  PubMed  Google Scholar 

  68. Zhang Z, Tsai PC, Ramezanli T, Michniak-Kohn BB (2013) Polymeric nanoparticles-based topical delivery systems for the treatment of dermatological diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol 5(3):205–218

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Garcês A, Amaral MH, Sousa Lobo JM, Silva AC (2018) Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: a review. Eur J Pharm Sci 112:159–167

    Article  CAS  PubMed  Google Scholar 

  70. Ganesan P, Narayanasamy D (2017) Lipid nanoparticles: different preparation techniques, characterization, hurdles, and strategies for the production of solid lipid nanoparticles and nanostructured lipid carriers for oral drug delivery. Sustain Chem Pharm 6:37–56

    Article  Google Scholar 

  71. Shields CW, White JP, Osta EG, Patel J, Rajkumar S, Kirby N et al (2018) Encapsulation and controlled release of retinol from silicone particles for topical delivery. J Control Release 278:37–48

    Article  CAS  PubMed  Google Scholar 

  72. Sinha P, Srivastava N, Rai VK, Mishra R, Ajayakumar PV, Yadav NP (2019) A novel approach for dermal controlled release of salicylic acid for improved anti-inflammatory action: combination of hydrophilic-lipophilic balance and response surface methodology. J Drug Deliv Sci Technol 52:870–884

    Article  CAS  Google Scholar 

  73. Plank R, Obst K, Yealland G, Calderón M, Hedtrich S, Martina Eckl K et al (2016) Nanogel-mediated protein replacement therapy for autosomal recessive congenital ichthyosis (ARCI). In: Proceedings of world congress on recent advances in nanotechnology 2016, pp 1–2, Paper No. NDDTE 105

  74. Plank R, Yealland G, Miceli E, Lima Cunha D, Graff P, Thomforde S et al (2019) Transglutaminase 1 replacement therapy successfully mitigates the autosomal recessive congenital ichthyosis phenotype in full-thickness skin disease equivalents. J Investig Dermatol 139:1191–1195

    Article  CAS  PubMed  Google Scholar 

  75. Mao K, Fan Z, Yuan J, Chen P, Yang J, Xu J (2017) Skin-penetrating polymeric nanoparticles incorporated in silk fibroin hydrogel for topical delivery of curcumin to improve its therapeutic effect on psoriasis mouse model. Colloids Surf B Biointerfaces 160:704–714

    Article  CAS  PubMed  Google Scholar 

  76. Sun L, Liu Z, Wang L, Cun D, Tong HHY, Yan R et al (2017) Enhanced topical penetration, system exposure and anti-psoriasis activity of two particle-sized, curcumin-loaded PLGA nanoparticles in hydrogel. J Control Release 254:44–54

    Article  CAS  PubMed  Google Scholar 

  77. Hönzke S, Gerecke C, Elpelt A, Zhang N, Unbehauen M, Kral V et al (2016) Tailored dendritic core-multishell nanocarriers for efficient dermal drug delivery: a systematic top-down approach from synthesis to preclinical testing. J Control Release 242:50–63

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This work was financially supported by a Grant from DGAPA-UNAM to Gerardo Leyva-Gómez (Grant number: PAPIIT TA 200318).

Author information

Authors and Affiliations

  1. Laboratorio de Medicina Genómica, Departamento de Genética, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, 14389, Mexico City, Mexico

    Hernán Cortés

  2. Laboratorio de Tecnología Farmacéutica, Facultad de Estudios Superiores Cuautitlán, Universidad Nacional Autónoma de México, Ave. 1o de Mayo S/N, Santa María las Torres, 54740, Cuautitlan Izcalli, Mexico

    María L. Del Prado-Audelo

  3. Departamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, Cd. Universitaria, Coyoacán, 04510, Mexico City, Mexico

    María L. Del Prado-Audelo, Zaida Urbán-Morlán & Gerardo Leyva-Gómez

  4. Universidad Autónoma del Estado de Morelos, Facultad de Farmacia, Av. Universidad 1001, Col. Chamilpa, 62209, Cuernavaca, Morelos, Mexico

    Sergio Alcalá-Alcalá

  5. CONACyT-Laboratorio de Biotecnología, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, 14389, Mexico City, Mexico

    Maykel González-Torres

  6. Instituto Tecnológico y de Estudios Superiores de Monterrey, 14380, Mexico City, Mexico

    Maykel González-Torres

  7. Laboratorio de Biología Molecular del Cáncer, UMIEZ, Facultad de Estudios Superiores Zaragoza, Universidad Nacional Autónoma de México, 09230, Mexico City, Mexico

    Octavio D. Reyes-Hernández

  8. Facultad de Medicina, Universidad Veracruzana, 94740, Mendoza, Veracruz, Mexico

    Manuel González-Del Carmen

Authors
  1. Hernán Cortés
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. María L. Del Prado-Audelo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zaida Urbán-Morlán
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sergio Alcalá-Alcalá
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maykel González-Torres
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Octavio D. Reyes-Hernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Manuel González-Del Carmen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gerardo Leyva-Gómez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Hernán Cortés or Gerardo Leyva-Gómez.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

This article does not contain any studies with human participants or animals performed by any of the authors; therefore, informed consent is not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cortés, H., Del Prado-Audelo, M.L., Urbán-Morlán, Z. et al. Pharmacological treatments for cutaneous manifestations of inherited ichthyoses. Arch Dermatol Res 312, 237–248 (2020). https://doi.org/10.1007/s00403-019-01994-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-019-01994-x

Keywords

Search

Navigation